Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer
- Determine the pharmacokinetics and pharmacodynamics of trastuzumab (Herceptin) and
paclitaxel in patients with HER2-overexpressing metastatic breast cancer.
- Provide access to trastuzumab and paclitaxel for these patients.
OUTLINE: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes and paclitaxel IV
over 1 hour weekly. Patients receive trastuzumab alone during course 1 and then in
combination with paclitaxel during subsequent courses. Courses repeat every 4 weeks until
patients achieve a sustained complete response of 8 weeks or disease progression occurs.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Susan E. Bates, MD
National Cancer Institute (NCI)
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|
|Holy Cross Hospital||Fort Lauderdale, Florida 33308|
|Mary Babb Randolph Center||Morgantown, West Virginia 26506-9162|